Antigen Immunogenicity
Antigen Immunogenicity - Related Videos
05:42
Using a Sandwich ELISA to Determine the Immunogenic Glycoprotein Content in a Vaccine
0 Views •
2025
This video showcases an indirect enzyme-linked immunosorbent assay or ELISA sandwich immunocapture assay designed to assess immunogenic glycoprotein levels in vaccines. The assay plate, containing glycoprotein-specific antibodies, is incubated with serially diluted vaccine samples, including reference and test vaccines, followed by immunoassay to quantify glycoprotein content in the test vaccine.
02:49
A Technique to Assess the Immune Response against an Antigen by Inducing Skin Inflammation
0 Views •
2025
This video demonstrates an in vivo technique to assess a test antigen by inducing skin inflammation in a murine model. The test antigen—a hapten in an oil/acetone solution—is topically applied to the skin of the mouse ear, and inflammation of the skin is assessed after an adequate period.
10:52
Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
0 Views •
Cited by 10 •
2010
Autoimmune hypophysitis can be reproduced in mice by injecting an extract of mouse pituitary proteins.
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
0 Views •
Cited by 9 •
2016
In this antigen-driven colitis model, OT-II CD4+ T cells expressing a red fluorescent protein were adoptively transferred into RAG-/- mice that express a green fluorescent protein in mononuclear phagocytes (MPs). The hosts were challenged with Escherichia coli (E.coli) expressing the ovalbumin protein (OVA) fused to a cyan fluorescent protein (CFP).
05:04
Viral Antigen Microarray Assay to Detect Antibody Isotypes in Serum Against Viral Antigen
0 Views •
2025
In this video, we demonstrate the process for detecting antibody isotypes in multiple human serum samples using a microarray slide printed with antigenic subtypes of influenza virus strains.
FAQs
These properties influence how efficiently antigen-presenting cells handle an antigen and display its fragments on major histocompatibility complex molecules. That presentation determines which T lymphocytes can be activated, while molecular features also affect recognition by B lymphocytes. Consequently, closely related antigens may produce different response strengths.
Major histocompatibility complex presentation does not describe the full activation context, but it provides a central route for displaying antigen-derived material to T lymphocytes. The efficiency and outcome of this step help determine whether cellular activation is strong or limited, linking antigen handling to the eventual adaptive response.
Dose and delivery influence the conditions under which immune cells encounter an antigen, so they can change the magnitude and character of the resulting response. These variables should therefore be considered alongside structure and molecular complexity when comparing candidate antigens or interpreting why one formulation produces stronger immunity than another.
Innate immune signals and co-stimulation provide biological cues that accompany antigen recognition and processing. They help shape whether B- and T-lymphocyte activation becomes robust or remains limited. This context explains why the presence of an antigen alone may not predict the strength of the adaptive response or the quality of resulting immunity.
Researchers can evaluate both antibody and cellular immunity to determine how an antigen affects distinct adaptive responses. Considering these two outcomes together provides a broader picture than measuring a single response type. Such assessments help compare candidate antigens, judge response strength, and examine whether immunity appears likely to support durable protection.
Vaccine development uses antigen immunogenicity to guide selection and design of candidates that can stimulate effective antibody and cellular responses. Researchers consider structure, complexity, dose, delivery, antigen presentation, innate signals, and co-stimulation together. These factors help explain why some vaccine approaches produce stronger or more durable protection than others.
Protein therapeutics may differ in how strongly they stimulate immune responses because antigen structure, size, complexity, dose, and delivery affect immune recognition and activation. Evaluating these influences can help researchers anticipate weak or limited responses, interpret antibody and cellular immunity, and understand why some antigens support more durable protection than others.